Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2008-2014

  Morris, V K ^a   Lucas, F A San ^a   Overman, M J ^a   Eng, C ^a   Morelli, M P ^a   Jiang, Z Q ^a   Luthra, R ^a   Meric Bernstam, F ^a   Maru, D ^a   Scheet, P ^a   Kopetz, S ^a   Vilar, E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

colorectal cancer; gene expression; KRAS; next generation sequencing; survival

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; CODON; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

AGED; BIOSYNTHESIS; CODON; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; SECONDARY;

AGED; CODON; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84964314170     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu252     Document Type: Article

References (16)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J Clin 63 (2013), 11–30.
2. Andreyev, H.J., Norman, A.R., Cunningham, D., et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer Inst 90 (1998), 675–684.
3. Forbes, S., Clements, J., Dawson, E., et al. Cosmic 2005. Br J Cancer 94 (2006), 318–322.
4. Scheffzek, K., Ahmadian, M.R., Kabsch, W., et al. The Ras–RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277 (1997), 333–338.
5. Trahey, M., McCormick, F., A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238 (1987), 542–545.
6. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765.
7. Tol, J., Koopman, M., Cats, A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009), 563–572.
8. Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
9. Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
10. Peeters, M., Oliner, K., Price, T., Cervantes, A., Analysis of KRAS/NRAS mutations in the phase 3 20050181 study of panitubumab + FOLFIRI versus FOLFIRI as second-line treatment for metastatic colorectal cancer. J Clin Oncol, 32(Suppl. 3), 2014, LBA387.
11. Der, C.J., Finkel, T., Cooper, G.M., Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44 (1986), 167–176.
12. San Lucas, F.A., Wang, G., Scheet, P., Peng, B., Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics 28 (2012), 421–422.
13. Modest, D., Welkersthal, L.V., Stintzing, S., et al. FOLFIRI plus cetuximab bersus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Ann Oncol 24 (2013), iv11–iv24.
14. Imamura, Y., Morikawa, T., Liao, X., et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18 (2012), 4753–4763.
15. Kim, M.J., Lee, H.S., Kim, J.H., et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer, 12, 2012, 347.
16. Tejpar, S., Celik, I., Schlichting, M., et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30 (2012), 3570–3577.